Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Multiple Sclerosis, Relapsing-Remitting 1Multiple Sclerosis 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Gliosarcoma 1Glioblastoma 1Carcinoma, Basal Cell 1

Interventions

aldesleukin 9Interleukin-2 9Nivolumab 7fludarabine phosphate 6Dacarbazine 6Cyclophosphamide 6fludarabine 5Temozolomide 4Ipilimumab 4Fluorouracil 4montanide ISA 51 3Surveys and Questionnaires 3Semaxinib 3Radiotherapy 3Radiation 3Mohs Surgery 3Educational Status 3Cisplatin 3Allovectin-7 3zanolimumab 2talabostat 2sonidegib 2poly ICLC 2binimetinib 2Whole-Body Irradiation 2Vinblastine 2Vemurafenib 2Tacrolimus 2Tablets 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Skin Neoplasms × Dimethyl Fumarate × Clear all
NCT06705608 2024-11-26

MS; FTY720

University of British Columbia

Completed
4,000 enrolled
Dermatologic

Carcinoma, Basal Cell, Melanoma, Multiple Sclerosis, Skin Neoplasms, Multiple Sclerosis, Relapsing-Remitting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡